We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Diagnosing Retinitis Pigmentosa by Determining the Ratio of Dolichol Variants in Plasma or Urine

By LabMedica International staff writers
Posted on 28 Oct 2013
A reliable, high-throughput, and cost-effective liquid chromatography-mass spectrometry technique for the quantitative measurement of dolichols in blood plasma or urine can unambiguously discriminate patients with retinitis pigmentosa from asymptotic carriers of the disease genes, and carriers from normal individuals.

Retinitis pigmentosa (RP) is one of the most common forms of inherited retinal degeneration. More...
This disorder is characterized by the progressive loss of photoreceptor cells and may eventually lead to blindness. There are multiple genes that, when mutated, can cause the retinitis pigmentosa phenotype. Among these mutations are the K42E and T206A mutations in the DHDDS (dehydrodolichol diphosphate synthase) gene.

Investigators at the University of Miami (FL, USA) and at Duke University (Durham, NC, USA),using liquid chromatography-mass spectrometry, observed a characteristic shortening of plasma and urinary dolichols in RP patients carrying the K42E and T206A mutations in the DHDDS gene. Dolichol-18 (D18) became the dominant dolichol species in patients compared to dolichol-19 (D19) in normal individuals.

The D18/D19 ratio was calculated and used as an index of dolichol length distribution. K42E/K42E and K42E/T206A patients were found to have significantly higher plasma and urinary D18/D19 ratios than K42E and T206A carriers. The ratios of carriers were significantly higher than normal individuals.

The methodologies and procedures used for dolichol profiling are reliable, high-throughput, and cost-effective. Dolichol profiling, complementary to genotyping, can be readily adapted as a test in the clinic for not only the diagnosis of patients but also identification of carriers with DHDDS or other genetic mutations that may impair dolichol biosynthesis.

"It is our vision that every patient who is affected with an inherited eye disease like RP should have access to a clinician who is knowledgeable about the diseases, as well as to affordable diagnostic testing and counseling," said contributing author Dr. Byron Lam, professor of ophthalmology at the University of Miami. "This diagnostic test is a powerful tool that will help in developing treatments for RP caused by DHDDS mutations."

The study was published in the September 27, 2013, online edition of the Journal of Lipid Research.

Related Links:
University of Miami
Duke University



New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Steam Sterilizer
Hi Vac II Line
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.